Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2021
Reporting Period: Event-based report for December 1, 2021.
Business Context: The Company is an emerging growth company incorporated in Nevada, with principal executive offices in Boca Raton, Florida. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB".
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material financial changes or operational shifts are reported in this document. The filing solely discloses the Company's participation in a scientific conference.
Guidance, Outlook, and Management Commentary
Event Reported: On December 1, 2021, Inmune Bio, Inc. issued a press release announcing two poster presentations at the 2021 British Society of Immunology Congress. The congress was held between November 28 and December 1 in Edinburgh, UK.
Exhibits: A copy of the press release is filed as Exhibit 99.1.
Outlook/Guidance: The filing text does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the event.
Investor Verification Checklist
- Verify the content of the press release filed as Exhibit 99.1 for details on the two poster presentations.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Review subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial figures.